Nvest Financial LLC Buys 1,689 Shares of Stryker Corporation $SYK

Nvest Financial LLC lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 33.2% during the first quarter, HoldingsChannel reports. The firm owned 6,776 shares of the medical technology company’s stock after acquiring an additional 1,689 shares during the quarter. Nvest Financial LLC’s holdings in Stryker were worth $2,226,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Westfuller Advisors LLC increased its holdings in Stryker by 6.5% during the first quarter. Westfuller Advisors LLC now owns 799 shares of the medical technology company’s stock worth $263,000 after buying an additional 49 shares during the last quarter. Kathmere Capital Management LLC lifted its stake in Stryker by 53.0% in the first quarter. Kathmere Capital Management LLC now owns 1,625 shares of the medical technology company’s stock valued at $534,000 after acquiring an additional 563 shares during the last quarter. Appleton Partners Inc. MA grew its position in shares of Stryker by 0.3% in the 1st quarter. Appleton Partners Inc. MA now owns 30,587 shares of the medical technology company’s stock valued at $10,051,000 after acquiring an additional 80 shares during the period. Bogart Wealth LLC increased its stake in shares of Stryker by 4.9% during the 1st quarter. Bogart Wealth LLC now owns 19,849 shares of the medical technology company’s stock worth $6,522,000 after purchasing an additional 931 shares during the last quarter. Finally, Columbia Bank increased its stake in shares of Stryker by 1.9% during the 1st quarter. Columbia Bank now owns 6,505 shares of the medical technology company’s stock worth $2,137,000 after purchasing an additional 120 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president directly owned 177 shares of the company’s stock, valued at $50,170.65. This represents a 95.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by company insiders.

Stryker Trading Down 0.0%

Shares of SYK stock opened at $326.41 on Monday. The firm has a 50 day moving average price of $309.80 and a two-hundred day moving average price of $338.75. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $125.13 billion, a PE ratio of 37.78, a price-to-earnings-growth ratio of 2.09 and a beta of 0.77. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analysts Set New Price Targets

A number of research firms recently commented on SYK. BTIG Research reduced their price target on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a report on Friday, May 1st. Truist Financial restated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Evercore set a $355.00 target price on Stryker in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on Stryker in a report on Friday, May 1st. Finally, Robert W. Baird set a $385.00 price target on Stryker in a research note on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.